Multiple sclerosis and vitamin D: an update

[1]  L. Packer,et al.  On the opinion of the European Commission “Scientific Committee on Food” regarding the tolerable upper intake level of vitamin E (2003) , 2005, European journal of nutrition.

[2]  J. Adams,et al.  Vitamin D as a Cytokine and Hematopoetic Factor , 2001, Reviews in Endocrine and Metabolic Disorders.

[3]  R. Heaney,et al.  Long-latency deficiency disease: insights from calcium and vitamin D. , 2003, The American journal of clinical nutrition.

[4]  T. Dwyer,et al.  Past exposure to sun, skin phenotype, and risk of multiple sclerosis: case-control study , 2003, BMJ : British Medical Journal.

[5]  A. Mackay-Sim,et al.  Vitamin d3 and brain development , 2003, Neuroscience.

[6]  C. Mathieu,et al.  Combination of a 1,25-dihydroxyvitamin D3 analog and a bisphosphonate prevents experimental autoimmune encephalomyelitis and preserves bone. , 2003, Bone.

[7]  B. Trapp,et al.  Axonal loss in the pathology of MS: consequences for understanding the progressive phase of the disease , 2003, Journal of the Neurological Sciences.

[8]  P. Brachet,et al.  Treatment of experimental autoimmune encephalomyelitis in rat by 1,25-dihydroxyvitamin D3 leads to early effects within the central nervous system , 2003, Acta Neuropathologica.

[9]  F. Cosman,et al.  Cytokine profile in patients with multiple sclerosis following vitamin D supplementation , 2003, Journal of Neuroimmunology.

[10]  R. Vieth,et al.  Age-related changes in the 25-hydroxyvitamin D versus parathyroid hormone relationship suggest a different reason why older adults require more vitamin D. , 2003, The Journal of clinical endocrinology and metabolism.

[11]  Opinion of the Scientific Committee on Food on the Tolerable Upper Intake Level of Vitamin K , 2003 .

[12]  M. Holick,et al.  Human serum 25-hydroxycholecalciferol response to extended oral dosing with cholecalciferol. , 2003, The American journal of clinical nutrition.

[13]  A. Ponsonby,et al.  Ultraviolet radiation and autoimmune disease: insights from epidemiological research. , 2002, Toxicology.

[14]  T. Meehan,et al.  The vitamin D receptor is necessary for 1α,25-dihydroxyvitamin D3 to suppress experimental autoimmune encephalomyelitis in mice ☆ , 2002 .

[15]  U. Segersten,et al.  Increased 25-hydroxyvitamin D3 1alpha-hydroxylase and reduced 25-hydroxyvitamin D3 24-hydroxylase expression in parathyroid tumors--new prospects for treatment of hyperparathyroidism with vitamin d. , 2002, The Journal of clinical endocrinology and metabolism.

[16]  L. Bernardinelli,et al.  An Ecologic Study of Geographical Variation in Multiple Sclerosis Risk in Central Sardinia, Italy , 2002, Neuroepidemiology.

[17]  S. Kikuchi,et al.  No association of vitamin D-binding protein gene polymorphisms in Japanese patients with MS , 2002, Journal of Neuroimmunology.

[18]  F. Barkhof,et al.  Seasonal variation in immune measurements and MRI markers of disease activity in MS , 2002, Neurology.

[19]  François Berger,et al.  New clues about vitamin D functions in the nervous system , 2002, Trends in Endocrinology & Metabolism.

[20]  C. Mathieu,et al.  The coming of age of 1,25-dihydroxyvitamin D(3) analogs as immunomodulatory agents. , 2002, Trends in molecular medicine.

[21]  M. Holick.  Vitamin D: the underappreciated D-lightful hormone that is important for skeletal and cellular health , 2002 .

[22]  T. Meehan,et al.  The vitamin D receptor is necessary for 1alpha,25-dihydroxyvitamin D(3) to suppress experimental autoimmune encephalomyelitis in mice. , 2002, Archives of biochemistry and biophysics.

[23]  H. DeLuca,et al.  Vitamin D: its role and uses in immunology 1 , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[24]  C. Mathieu,et al.  In Vitro and In Vivo Analysis of the Immune System of Vitamin D Receptor Knockout Mice , 2001, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[25]  N. Maurits,et al.  Early prediction of a benign course of multiple sclerosis on clinical grounds: a systematic review , 2001, Multiple sclerosis.

[26]  J. Goverman,et al.  Rag-1-dependent cells are necessary for 1,25-dihydroxyvitamin D3 prevention of experimental autoimmune encephalomyelitis , 2001, Journal of Neuroimmunology.

[27]  L. Adorini,et al.  Regulatory T Cells Induced by 1α,25-Dihydroxyvitamin D3 and Mycophenolate Mofetil Treatment Mediate Transplantation Tolerance1 , 2001, The Journal of Immunology.

[28]  Terence Dwyer,et al.  Regional Variation in Multiple Sclerosis Prevalence in Australia and Its Association with Ambient Ultraviolet Radiation , 2001, Neuroepidemiology.

[29]  P. Lips,et al.  Vitamin D deficiency and secondary hyperparathyroidism in the elderly: consequences for bone loss and fractures and therapeutic implications. , 2001, Endocrine reviews.

[30]  R. Kumar,et al.  Dendritic cell modulation by 1α,25 dihydroxyvitamin D3 and its analogs: A vitamin D receptor-dependent pathway that promotes a persistent state of immaturity in vitro and in vivo , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[31]  G. Rosati,et al.  Neurol Sci (2001) 22:163-165 Springer-Verlag 2001 , 2022 .

[32]  M. Rovaris,et al.  Effects of seasons on magnetic resonance imaging–measured disease activity in patients with multiple sclerosis , 2001, Annals of neurology.

[33]  A. Howie,et al.  Extrarenal Expression of 25-Hydroxyvitamin D3-1α-Hydroxylase1 , 2001 .

[34]  R. Vieth,et al.  Efficacy and safety of vitamin D3 intake exceeding the lowest observed adverse effect level. , 2001, The American journal of clinical nutrition.

[35]  L. Valiquette,et al.  Expression of CYP27A, a gene encoding a vitamin D‐25 hydroxylase in human liver and kidney , 2001, Clinical endocrinology.

[36]  L. Adorini,et al.  Regulatory T Cells Induced by 1 ,25-Dihydroxyvitamin D3 and Mycophenolate Mofetil Treatment Mediate Transplantation Tolerance , 2001 .

[37]  P M Stewart,et al.  Extrarenal expression of 25-hydroxyvitamin d(3)-1 alpha-hydroxylase. , 2001, The Journal of clinical endocrinology and metabolism.

[38]  C. Hayes.  Vitamin D: a natural inhibitor of multiple sclerosis , 2000, Proceedings of the Nutrition Society.

[39]  D. Zehnder,et al.  1alpha-Hydroxylase and the action of vitamin D. , 2000, Journal of molecular endocrinology.

[40]  P. White,et al.  The Multifunctional Properties and Characteristics of Vitamin D-binding Protein , 2000, Trends in Endocrinology & Metabolism.

[41]  M. Holick,et al.  Decreased bioavailability of vitamin D in obesity. , 2000, The American journal of clinical nutrition.

[42]  R. Vieth,et al.  Vitamin D and seasonal fluctuations of gadolinium‐enhancing magnetic resonance imaging lesions in multiple sclerosis , 2000, Annals of neurology.

[43]  A. Cross,et al.  A catalyst of peroxynitrite decomposition inhibits murine experimental autoimmune encephalomyelitis , 2000, Journal of Neuroimmunology.

[44]  P. Brachet,et al.  Rat oligodendrocytes express the vitamin D3 receptor and respond to 1,25‐dihydroxyvitamin D3 , 2000, Glia.

[45]  M. Horowitz,et al.  Vitamin D status: effects on parathyroid hormone and 1, 25-dihydroxyvitamin D in postmenopausal women. , 2000, The American journal of clinical nutrition.

[46]  Mustafa Dosemeci,et al.  Mortality from multiple sclerosis and exposure to residential and occupational solar radiation: a case-control study based on death certificates , 2000, Occupational and environmental medicine.

[47]  C. Mathieu,et al.  Analogs of 1,25-dihydroxyvitamin D3 as dose-reducing agents for classical immunosuppressants. , 2000, Transplantation.

[48]  D. English,et al.  The age-range of risk of developing multiple sclerosis: evidence from a migrant population in Australia. , 2000, Brain : a journal of neurology.

[49]  C. Mathieu,et al.  Identification and immune regulation of 25‐hydroxyvitamin D‐1‐α‐hydroxylase in murine macrophages , 2000, Clinical and experimental immunology.

[50]  L. Adorini,et al.  1α,25-Dihydroxyvitamin D3 Inhibits Differentiation, Maturation, Activation, and Survival of Dendritic Cells Leading to Impaired Alloreactive T Cell Activation , 2000, The Journal of Immunology.

[51]  N. Risch,et al.  Genetic analysis of vitamin D related genes in Canadian multiple sclerosis patients , 2000, Neurology.

[52]  C. Gössl,et al.  Seasonal fluctuations of gadolinium‐enhancing magnetic resonance imaging lesions in multiple sclerosis , 2000, Annals of neurology.

[53]  G. Martino,et al.  Inhibition of Th1 development and treatment of chronic‐relapsing experimental allergic encephalomyelitis by a non‐hypercalcemic analogue of 1,25‐dihydroxyvitamin D3 , 2000, European journal of immunology.

[54]  F. Nashold,et al.  1,25-Dihydroxyvitamin D3 treatment decreases macrophage accumulation in the CNS of mice with experimental autoimmune encephalomyelitis , 2000, Journal of Neuroimmunology.

[55]  C. Mathieu,et al.  Recent developments in the use of vitamin D analogues , 1998, Current opinion in nephrology and hypertension.

[56]  L. Adorini,et al.  1 Alpha,25-dihydroxyvitamin D3 inhibits differentiation, maturation, activation, and survival of dendritic cells leading to impaired alloreactive T cell activation. , 2000, Journal of immunology.

[57]  J. Cauley,et al.  Molecular epidemiology of vitamin D receptor gene variants. , 2000, Epidemiologic reviews.

[58]  W. Cowden,et al.  Our shifting understanding of the role of nitric oxide in autoimmune encephalomyelitis: a review , 1999, Journal of Neuroimmunology.

[59]  H. DeLuca,et al.  Dietary calcium is a major factor in 1,25-dihydroxycholecalciferol suppression of experimental autoimmune encephalomyelitis in mice. , 1999, The Journal of nutrition.

[60]  M. Meurer,et al.  Expression of vitamin D3 25-hydroxylase (CYP27) mRNA after induction by vitamin D3 or UVB radiation in keratinocytes of human skin equivalents – a preliminary study , 1999, Archives of Dermatological Research.

[61]  B. Trapp,et al.  Pathogenesis of tissue injury in MS lesions , 1999, Journal of Neuroimmunology.

[62]  J. Noseworthy.  Progress in determining the causes and treatment of multiple sclerosis , 1999, Nature.

[63]  K. Miyasaka,et al.  Association of vitamin D receptor gene polymorphism with multiple sclerosis in Japanese , 1999, Journal of the Neurological Sciences.

[64]  K. Miyazono,et al.  Positive and Negative Modulation of Vitamin D Receptor Function by Transforming Growth Factor-β Signaling through Smad Proteins* , 1999, The Journal of Biological Chemistry.

[65]  R. Vieth,et al.  Vitamin D supplementation, 25-hydroxyvitamin D concentrations, and safety. , 1999, The American journal of clinical nutrition.

[66]  K. Miyazono,et al.  Convergence of transforming growth factor-beta and vitamin D signaling pathways on SMAD transcriptional coactivators. , 1999, Science.

[67]  G. Peres,et al.  Vitamin D Status During Puberty in French Healthy Male Adolescents , 1999, Osteoporosis International.

[68]  J. Eisman,et al.  Molecular mechanism of vitamin D receptor action , 1998, Inflammation Research.

[69]  D. Kwiatkowski,et al.  1,25-Dihydroxyvitamin D3 Induces Nitric Oxide Synthase and Suppresses Growth of Mycobacterium tuberculosis in a Human Macrophage-Like Cell Line , 1998, Infection and Immunity.

[70]  N. Van Rooijen,et al.  Immune invasion of the central nervous system parenchyma and experimental allergic encephalomyelitis, but not leukocyte extravasation from blood, are prevented in macrophage-depleted mice. , 1998, Journal of immunology.

[71]  J. Herbert,et al.  Fracture history and bone loss in patients with MS , 1998, Neurology.

[72]  P. Lips,et al.  Ultraviolet Irradiation Corrects Vitamin D Deficiency and Suppresses Secondary Hyperparathyroidism in the Elderly , 1998, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[73]  P. Stehle,et al.  Seasonal variations in vitamin D status and calcium absorption do not influence bone turnover in young women , 1998, European Journal of Clinical Nutrition.

[74]  H. DeLuca,et al.  1,25-dihydroxyvitamin D3 is a positive regulator for the two anti-encephalitogenic cytokines TGF-beta 1 and IL-4. , 1998, Journal of immunology.

[75]  J. Riancho,et al.  Seasonal Deficiency of Vitamin D in Children: A Potential Target for Osteoporosis‐Preventing Strategies? , 1998, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[76]  M. Holick,et al.  Redefining vitamin D insufficiency , 1998, The Lancet.

[77]  P. Brachet,et al.  Expression of inducible nitric oxide synthase during rat brain inflammation: Regulation by 1,25‐dihydroxyvitamin D3 , 1998, Glia.

[78]  E. Gunter,et al.  Hypovitaminosis D in medical inpatients. , 1998, The New England journal of medicine.

[79]  R. Heaney,et al.  Vitamin D and its Major Metabolites: Serum Levels after Graded Oral Dosing in Healthy Men , 1998, Osteoporosis International.

[80]  S. Amor,et al.  Cell biology of autoimmune diseases. , 1998, International review of cytology.

[81]  M. Cippitelli,et al.  Inhibition of IL-12 production by 1,25-dihydroxyvitamin D3. Involvement of NF-kappaB downregulation in transcriptional repression of the p40 gene. , 1998, The Journal of clinical investigation.

[82]  S. Scharla.  Prevalence of Subclinical Vitamin D Deficiency in Different European Countries , 1998, Osteoporosis International.

[83]  C. Mathieu,et al.  Synergism between sirolimus and 1,25-dihydroxyvitamin D3 in vitro and in vivo , 1997, Journal of Neuroimmunology.

[84]  F. Glorieux,et al.  The 25‐Hydroxyvitamin D 1‐Alpha‐Hydroxylase Gene Maps to the Pseudovitamin D‐Deficiency Rickets (PDDR) Disease Locus , 1997, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[85]  K. Lauer.  Diet and multiple sclerosis , 1997, Neurology.

[86]  A. Compston.  Genetic epidemiology of multiple sclerosis. , 1997, Journal of neurology, neurosurgery, and psychiatry.

[87]  P. Brachet,et al.  1,25-Dihydroxyvitamin D3 inhibits the expression of inducible nitric oxide synthase in rat central nervous system during experimental allergic encephalomyelitis. , 1997, Brain research. Molecular brain research.

[88]  P. Galan,et al.  Prevalence of Vitamin D Insufficiency in an Adult Normal Population , 1997, Osteoporosis International.

[89]  H. van den Berg.  Bioavailability of vitamin D. , 1997, European journal of clinical nutrition.

[90]  J. Scott.  Bioavailability of vitamin B12. , 1997, European journal of clinical nutrition.

[91]  B. Dawson-Hughes,et al.  Plasma calcidiol, season, and serum parathyroid hormone concentrations in healthy elderly men and women. , 1997, The American journal of clinical nutrition.

[92]  M. Seibel,et al.  Lower serum 25-hydroxyvitamin D is associated with increased bone resorption markers and lower bone density at the proximal femur in normal females: a population-based study. , 2009, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

[93]  P. Brachet,et al.  1,25 Dihydroxyvitamin D3 Exerts Regional Effects in the Central Nervous System during Experimental Allergic Encephalomyelitis , 1996, Journal of neuropathology and experimental neurology.

[94]  H. DeLuca,et al.  1,25-Dihydroxyvitamin D3 reversibly blocks the progression of relapsing encephalomyelitis, a model of multiple sclerosis. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[95]  Moses Rodriguez,et al.  Distinct Patterns of Multiple Sclerosis Pathology Indicates Heterogeneity in Pathogenesis , 1996, Brain pathology.

[96]  B. Weinshenker,et al.  Epidemiology of multiple sclerosis. , 1996, Neurologic clinics.

[97]  S E Whitmore,et al.  Vitamin D deficiency in homebound elderly persons. , 1996, JAMA.

[98]  S. Linden,et al.  Aggravation of experimental allergic encephalomyelitis (EAE) by administration of nitric oxide (NO) synthase inhibitors , 1996, Clinical and experimental immunology.

[99]  P Laing,et al.  Multiple sclerosis: sunlight, diet, immunology and aetiology. , 1996, Medical hypotheses.

[100]  M. Mcdaniel,et al.  Experimental allergic encephalomyelitis in the rat is inhibited by aminoguanidine, an inhibitor of nitric oxide synthase , 1996, Journal of Neuroimmunology.

[101]  C. Hutter,et al.  Carbon monoxide--does fetal exposure cause sudden infant death syndrome? , 1996, Medical hypotheses.

[102]  C. Martyn,et al.  Migrant studies in multiple sclerosis , 1995, Progress in Neurobiology.

[103]  S. Sasaki,et al.  Nutrition, latitude, and multiple sclerosis mortality: an ecologic study. , 1995, American journal of epidemiology.

[104]  R. Bouillon,et al.  Prevention of murine experimental allergic encephalomyelitis: cooperative effects of cyclosporine and 1 α, 25-(OH)2D3 , 1995, Journal of Neuroimmunology.

[105]  C. Mathieu,et al.  Immunomodulatory effects of 1,25‐dihydroxyvitamin D3 , 1995, Current opinion in nephrology and hypertension.

[106]  R. Bouillon,et al.  Structure-function relationships in the vitamin D endocrine system. , 1995, Endocrine reviews.

[107]  J. Guillemant,et al.  Comparison of the biochemical and hormonal acute effects of calcium salts. , 1995, Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA.

[108]  G. Reddy,et al.  1,25-Dihydroxy-24-OXO-16ene-vitamin D3, a renal metabolite of the vitamin D analog 1,25-dihydroxy-16ene-vitamin D3, exerts immunosuppressive activity equal to its parent without causing hypercalcemia in vivo. , 1994, Endocrinology.

[109]  A. Sadovnick,et al.  The role of genetic factors in multiple sclerosis susceptibility , 1994, Journal of Neuroimmunology.

[110]  J. Herbert,et al.  High prevalence of vitamin D deficiency and reduced bone mass in multiple sclerosis , 1994, Neurology.

[111]  P. Brachet,et al.  Synthesis of 1,25‐dihydroxyvitamin D3 by rat brain macrophages in vitro , 1994, Journal of neuroscience research.

[112]  A. Cross,et al.  Aminoguanidine, an inhibitor of inducible nitric oxide synthase, ameliorates experimental autoimmune encephalomyelitis in SJL mice. , 1994, The Journal of clinical investigation.

[113]  N. Roberts,et al.  Seasonal Variation in Serum 25-Hydroxy Vitamin D3 Does Not Affect 1,25-Dihydroxy Vitamin D , 1994, Annals of clinical biochemistry.

[114]  G. Ebers.  Genetics and multiple sclerosis: An overview , 1994, Annals of neurology.

[115]  F Duboeuf,et al.  Vitamin D3 and calcium to prevent hip fractures in elderly women. , 1992, The New England journal of medicine.

[116]  M. Walters.  Newly identified actions of the vitamin D endocrine system. , 1992, Endocrine reviews.

[117]  M. McKenna,et al.  Differences in vitamin D status between countries in young adults and the elderly. , 1992, The American journal of medicine.

[118]  A. C. Maiyar,et al.  1,25(OH)2-vitamin D3, a steroid hormone that produces biologic effects via both genomic and nongenomic pathways , 1992, The Journal of Steroid Biochemistry and Molecular Biology.

[119]  J. Adams,et al.  1,25‐Dihydroxyvitamin D3 inhibits the passive transfer of cellular immunity by a myelin basic protein‐specific T cell clone , 1992, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[120]  J. Lemire,et al.  1,25-dihydroxyvitamin D3 prevents the in vivo induction of murine experimental autoimmune encephalomyelitis. , 1991, The Journal of clinical investigation.

[121]  L. Harbige,et al.  A review of the aetiology of multiple sclerosis: an ecological approach. , 1991, Annals of human biology.

[122]  J. Pike,et al.  Vitamin D3 receptors: structure and function in transcription. , 1991, Annual review of nutrition.

[123]  B. Uitdehaag,et al.  Suppression of experimental allergic encephalomyelitis in Lewis rats after elimination of macrophages , 1990, The Journal of experimental medicine.

[124]  M. Holick,et al.  Sunlight regulates the cutaneous production of vitamin D3 by causing its photodegradation. , 1989, The Journal of clinical endocrinology and metabolism.

[125]  H. Koeffler,et al.  The role of the vitamin D endocrine system in health and disease. , 1989, The New England journal of medicine.

[126]  P. Delmas,et al.  The effect of vitamin D supplementation on vitamin D status and parathyroid function in elderly subjects. , 1988, The Journal of clinical endocrinology and metabolism.

[127]  P. Elias,et al.  1,25-Dihydroxyvitamin D production and receptor binding in human keratinocytes varies with differentiation. , 1988, The Journal of biological chemistry.

[128]  M. Holick,et al.  The role of sunlight in the cutaneous production of vitamin D3. , 1988, Annual review of nutrition.

[129]  M. Holick,et al.  Sunscreens suppress cutaneous vitamin D3 synthesis. , 1987, The Journal of clinical endocrinology and metabolism.

[130]  J. Auwerx,et al.  Vitamin D status in the elderly: seasonal substrate deficiency causes 1,25-dihydroxycholecalciferol deficiency. , 1987, The American journal of clinical nutrition.

[131]  M. Holick.  Photosynthesis of vitamin D in the skin: effect of environmental and life-style variables. , 1987, Federation proceedings.

[132]  R. Kumar,et al.  The metabolism and mechanism of action of 1,25-dihydroxyvitamin D3. , 1986, Kidney international.

[133]  P. Goldberg,et al.  Multiple sclerosis: decreased relapse rate through dietary supplementation with calcium, magnesium and vitamin D. , 1986, Medical hypotheses.

[134]  S. Manolagas,et al.  Interactions of 1,25-dihydroxyvitamin D3 and the immune system , 1985, Molecular and Cellular Endocrinology.

[135]  J. Adams,et al.  Isolation and structural identification of 1,25-dihydroxyvitamin D3 produced by cultured alveolar macrophages in sarcoidosis. , 1985, The Journal of clinical endocrinology and metabolism.

[136]  H. DeLuca,et al.  Induction of macrophage differentiation of human normal and leukemic myeloid stem cells by 1,25-dihydroxyvitamin D3 and its fluorinated analogues. , 1984, Cancer research.

[137]  L. Glimcher,et al.  1,25-Dihydroxyvitamin D3 inhibits antigen-induced T cell activation. , 1984, Journal of immunology.

[138]  H. Weiner,et al.  Prevention of experimental allergic encephalomyelitis (EAE) in the SJL/J mouse by whole body ultraviolet irradiation. , 1984, Journal of immunology.

[139]  R. Goldman.  Induction of a high phagocytic capability in P388D1, a macrophage-like tumor cell line, by 1 alpha, 25-dihydroxyvitamin D3. , 1984, Cancer research.

[140]  S. Krane,et al.  Specific high-affinity receptors for 1,25-dihydroxyvitamin D3 in human peripheral blood mononuclear cells: presence in monocytes and induction in T lymphocytes following activation. , 1983, The Journal of clinical endocrinology and metabolism.

[141]  S. Manolagas,et al.  1,25-dihydroxyvitamin D3 receptors in human leukocytes. , 1983, Science.

[142]  L Perelmutter,et al.  IgG4 and the immune system , 1983, Clinical reviews in allergy.

[143]  G. Beebe,et al.  Epidemiology of multiple sclerosis in U.S. veterans: 2. Latitude, climate and the risk of multiple sclerosis. , 1983, Journal of chronic diseases.

[144]  J. Adams,et al.  INCREASED SKIN PIGMENT REDUCES THE CAPACITY OF SKIN TO SYNTHESISE VITAMIN D3 , 1982, The Lancet.

[145]  F. V. Van Ginkel,et al.  Histomorphometric profile and vitamin D status in patients with femoral neck fracture. , 1982, Metabolic bone disease & related research.

[146]  H. DeLuca,et al.  Absence of seasonal variation in serum concentrations of 1,25-dihydroxyvitamin D despite a rise in 25-hydroxyvitamin D in summer. , 1981, The Journal of clinical endocrinology and metabolism.

[147]  H. De Luca,et al.  Calcitroic acid: biological activity and tissue distribution studies. , 1981, Archives of biochemistry and biophysics.

[148]  T. Stamp.  Factors in human vitamin D nutrition and in the production and cure of classical rickets , 1975, Proceedings of the Nutrition Society.

[149]  B. Agranoff,et al.  Diet and the geographical distribution of multiple sclerosis. , 1974, Lancet.

[150]  M. Alter,et al.  Multiple sclerosis and nutrition. , 1974, Archives of neurology.

[151]  P. Goldberg.  Multiple sclerosis: vitamin D and calcium as environmental determinants of prevalence: (A viewpoint) part 2. biochemical and genetic factors , 1974 .

[152]  P. Goldberg.  Multiple sclerosis: vitamin D and calcium as environmental determinants of prevalence. (A viewpoint). Part 1. Sunlight, dietary factors and epidemiology. , 1974 .

[153]  Intakes for Calcium , Phosphorus , Magnesium , Vitamin D , and Fluoride , 1974 .

[154]  P. Y. Paterson,et al.  Cyclophosphamide inhibition of experimental allergic encephalomyelitis and cellular transfer of the disease in Lewis rats. , 1969, Journal of immunology.

[155]  D. Mcalpine.  The benign form of multiple sclerosis. A study based on 241 cases seen within three years of onset and followed up until the tenth year or more of the disease. , 1961, Brain : a journal of neurology.

[156]  E. Acheson,et al.  SOME COMMENTS ON THE RELATIONSHIP OF THE DISTRIBUTION OF MULTIPLE SCLEROSIS TO LATITUDE, SOLAR RADIATION, AND OTHER VARIABLES , 1960, Acta psychiatrica Scandinavica. Supplementum.

[157]  R. Swank.  Treatment of multiple sclerosis with low-fat diet. , 1960, A.M.A. archives of neurology and psychiatry.

[158]  R. Swank,et al.  Multiple sclerosis in rural Norway its geographic and occupational incidence in relation to nutrition. , 1952, The New England journal of medicine.

[159]  A STORY OF NUTRITIONAL RESEARCH , 1951 .

[160]  E. Mellanby.  A Story of Nutritional Research. The Effect of some Dietary Factors on Bones and the Nervous System. , 1950 .